Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2004-01-29
2008-08-05
Ungar, Susan (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S155100, C424S178100, C424S181100, C424S174100, C530S388100, C530S388200, C530S388800, C530S387700, C530S387300
Reexamination Certificate
active
07407656
ABSTRACT:
The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.
REFERENCES:
patent: 4474893 (1984-10-01), Reading
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5359836 (1994-11-01), Zeuner et al.
patent: 5571894 (1996-11-01), Weis et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5728815 (1998-03-01), Chung et al.
patent: 5738867 (1998-04-01), Spitler
patent: 5856136 (1999-01-01), Au-young
patent: 5980896 (1999-11-01), Hellstrom et al.
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6194152 (2001-02-01), Laus et al.
patent: 6207380 (2001-03-01), Billing-Medel et al.
patent: 6258939 (2001-07-01), Reiter et al.
patent: 6261789 (2001-07-01), Reiter et al.
patent: 6261791 (2001-07-01), Reiter et al.
patent: 6267960 (2001-07-01), Reiter et al.
patent: 6541212 (2003-04-01), Reiter et al.
patent: 6756036 (2004-06-01), Reiter et al.
patent: 6790939 (2004-09-01), Reiter et al.
patent: 6824780 (2004-11-01), Devaux et al.
patent: 6825326 (2004-11-01), Reiter et al.
patent: 6881822 (2005-04-01), Reiter et al.
patent: 6890749 (2005-05-01), Billing-Medel et al.
patent: 6960443 (2005-11-01), Reiter et al.
patent: 6979730 (2005-12-01), Reiter et al.
patent: 7229960 (2007-06-01), Pero et al.
patent: 2002/0119157 (2002-08-01), Reiter et al.
patent: 2003/0070185 (2003-04-01), Jakobovits et al.
patent: 2003/0113820 (2003-06-01), Reiter et al.
patent: 2004/0018571 (2004-01-01), Reiter et al.
patent: 2004/0180002 (2004-09-01), Young et al.
patent: 2004/0197328 (2004-10-01), Young et al.
patent: 2005/0003465 (2005-01-01), Reiter et al.
patent: 2005/0059099 (2005-03-01), Reiter et al.
patent: 2005/0152909 (2005-07-01), Reiter et al.
patent: 2005/0169930 (2005-08-01), Reiter et al.
patent: 2005/0282187 (2005-12-01), Billing-Medel et al.
patent: WO 91/09967 (1991-07-01), None
patent: WO 98/40403 (1998-09-01), None
patent: WO 98/51805 (1998-11-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Drexler et al (Leukemia and Lymphoma, 1993, 9:1-25).
Zellner et al (Clin. Can. Res., 1998, 4:1797-1802).
Embleton et al (Immunol Ser, 1984, 23:181-207).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444, see abstract in particular).
Benedict et al (J. Exp. Medicine, 2001, 193(1)89-99).
Singh et al (Glycobiology, 2001, vol. 11, pp. 587-592).
Bowie et al (Science, 1990, 257:1306-1310).
Rudikoff et al, (PNAS, USA, 1982, 79: 1979).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Dillman (Annals of Internal Medicine, 1989; 111:592-603).
Jiang et al (JBC, 2003, 278(7) 4763-4769).
Matsushita et al (FEBS Letters, 1999, vol. 443, pp. 348-352).
Capizzi, R.L., “Principles of Treatment of Cancer,” Chapter 72In Internal Medicine, 4th edition, Stein, J. ed., Elsevier Science, 1994, pp. 707-729.
Carter, S.K. et al.,Chemotherapy of Cancer, Second Edition, John Wiley & Sons: New York, 1981, Appendix C—pp. 361-367.
Chatterjee, M.B. et al., “Idiotypic Antibody Immunotherapy of Cancer,”Cancer Immunol. Immunither., 1994, vol. 38, pp. 75-82.
Greenspan, N.S. et al., “Defining Epitopes: It's Not As Easy As It Seems,”Nature Biotechnology, Oct. 1999, vol. 17, pp. 936-937.
Gu, Z. et al., “Anti-Prostate Stem Cell Antigen Monoclonal Antibody 1G8 Induces Cell Death In vitro and Inhibits Tumor Growth In Vivo via a Fc-Independent Mechanism,”Cancer Research, Oct. 15, 2005, vol. 65, No. 20, pp. 9495-9500.
Hammer, R.E. et al., “Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human β2m: An Animal Model of HLA-B27-Associated Human Disorders,”Cell, Nov. 30, 1990, vol. 63, pp. 1099-1112.
Kaiser, J., “First Pass at Cancer Genome Reveals Complex Landscape,”Science, Sep. 8, 2006, vol. 313, p. 1370.
Knight, P., “The Carbohydrate Frontier,”Bio/Technology, Jan. 1989, vol. 7, No. 1, pp. 35-40.
Krontiris, T.G., “Molecular and Cellular Biology of Cancer,” Chapter 71In Internal Medicine, 4th edition, Stein, J. ed., Elsevier Science, 1994, pp. 699-707.
Lorimer, I.A.J. et al., “Recombinant Immunotoxins Specific for a Mutant Epidermal Growth Factor Receptor: Targeting with a Single Chain Antibody Variable Domain Isolated by Phage Display,”Proc. Natl. Acad. Sci. USA, Dec. 1996, vol. 93, pp. 14815-14820.
Reiter, R.E. et al. “Prostate Stem Cell Antigen: A Cell Surface Marker Overexpressed in Prostate Cancer,” Feb. 1998,Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1735-1740.
Seaver, S.S., “Monoclonal Antibodies in Industry: More Difficult Than Originally Thought,”Genetic Engineering News, Aug. 1994, vol. 14, pp. 21-22.
Sevier, E.D. et al., “Monoclonal Antibodies in Clinical Immunology,”Clin. Chem. 1981, vol. 27, No. 11, pp. 1797-1806.
Sharma, J.J. et al., “Phase II Study of Flutamide as Second Line Chemotherapy in Patients With Advanced Pancreatic Cancer,”Investigational New Drugs, 1997, vol. 15, pp. 361-364.
Sharon, J. et al., “Expression of a VHCKChimaeric Protein in Mouse Myeloma Cells,”Nature, May 1984, vol. 309, No. 5966, pp. 364-367.
Thomas, G.D. et al., “Antibodies for Tumor Immunodetection and Methods for Antibody Radiolabelling,” Chapter 8In Antibodies vol. II, A Practical Approach, Catty, D. ed., IRL Press, Oxford University Press, 1989, pp. 223-245.
Vitetta, E.S. et al., “Section 21.2. Immunotoxins,”In Biologic Therapy of Cancer, J.B. Lippincott Company, 1991, pp. 482-495.
Bellone, M. et al.,Cancer immunotherapy: synthetic and natural peptides in the balance, Immunology Today, 20(10): 457-462 (1999) U.S. Appl. No. 09/854,811 Cited in PTO-892.
Benjamin, L. et al.,A plasticity window for blood vessel remodeling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF, Development 125:1519-1598; see Abstract pp. 1594-1596 (1998)U.S. Appl. No. 10/225,779 cited in PTO-892.
Bork, P. et al.,Go hunting in sequence databases but watch out for the traps, Trends in Genetics 12:425-427 (1996) U.S. Appl. No. 10/225,779 Cited in PTO-892.
Brenner, S.,Errors in genome annotation, Trends in Genetics 15:132-133 (1999) U.S. Appl. No. 10/225,779 Cited in PTO-892.
Curti, B.Physical barriers to drug delivery in tumors, Crit. Rev. in Oncology/Hematology 14:29-39 (1993) U.S. Appl. No. 10/769,479 Cited in PTO-892.
Dannull, J. et al.,Prostate Stem Cell Antigen Is a Promising Candidate for Immunotherapy of Advanced Prostate Cancer, Cancer Research, vol. 60, pp. 5522-5528, Oct. 1, 2000 U.S. Appl. No. 09/854,811.
Doerks, T. et al.,Protein annotation: detective work for function prediction, Trends in Genetics 14:248-250 (1998) U.S. Appl. No. 10/225,779 Cited in PTO-892.
Ezzell, C.,Cancer “Vaccines”: An Idea Whose Time Has Come, The J. of NIH Research 7:45-49 (1995) U.S. Appl. No. 09/854,811 Cited in PTO-892.
Fu, L. et al,Translational regulation of human p53 gene expression, EMBO Journal 15:4392-4401 (1996) U.S. Appl. No. 10/225,784 Cited INPTO-892.
Gaiger, A. et al.,Immunity to WT1 in the animal model and in patients with acute myeloid leukemia, Blood 96:1480-89 (2000) U.S. Appl. No. 09/854,811 Cited in PTO-892.
Green et al.,Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACS, Nature Genetics 7:13-21 (1994) U.S. Appl. No. 09/359,326 Cited in PTO-892.
Gura, T.,Systems for Identifying New Drugs are Often Faulty, Science 278:1041-1042 (1997) U.S. Appl. No. 09/854,811 Cited in PTO-892.
Jain, R.,Barriers to Drug Delivery in Solid Tumors, Scientific American pp. 58-65 (Jul. 19
Jakobovits Aya
Reiter Robert E.
Saffran Douglas C.
Witte Owen N.
Agensys, Inc.
Reddig Peter J.
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Ungar Susan
LandOfFree
PSCA: prostate stem cell antigen and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PSCA: prostate stem cell antigen and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PSCA: prostate stem cell antigen and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002202